Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Miglitol in Type 2 Diabetes with Insulin
NCT00213070Phase 3Completed
- Sponsor
- Sanwa Kagaku Kenkyusho Co., Ltd.
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Miglitol + Insulin with Placebo + Insulin (2 arms). Primary endpoints: 1-hour Postprandial Plasma Glucose at 12 weeks, 2-hour Postprandial Plasma Glucose at 12 weeks and 1 more. Status: completed.
02
Drugs
miglitol
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00213070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00213070.